Drug intelligence / Profile preview

SIR-T PSMA

Development stage: Preclinical
Lead developer: Abeona Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

SIR-T PSMA is an engineered cell therapy candidate developed by Angeles Therapeutics for the treatment of PSMA-expressing malignancies, primarily prostate cancer. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR-T) platform, which engineers T cells to express a receptor that recognizes Prostate-Specific Membrane Antigen (PSMA). This SIR-T architecture is designed to engage the natural T-cell signaling machinery more effectively than traditional Chimeric Antigen Receptors (CARs), potentially enhancing the persistence and anti-tumor activity of the cells within the immunosuppressive solid tumor microenvironment. The program is currently undergoing IND-enabling studies.

Other names: SIR-T PSMA

Beyond the preview

Go deeper on SIR-T PSMA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-T PSMA.

Explore the full profile